Aphinity, trial summary

A randomised clinical trial investigating the effect of pertuzumab versus placebo in people with operable HER2-positive eBC

        Z

NCT01358877    



Studied treatment
Six to eight cycles of chemotherapy (anthracycline or non-anthracycline-containing regimen) with Perjeta and Herceptin, followed by Perjeta and Herceptin every three weeks for a total of one year (52 weeks) of treatment
Control treatment
Six to eight cycles of chemotherapy (anthracycline or non-anthracycline-containing regimen) with placebo and Herceptin, followed by placebo and Herceptin every three weeks for a total of one year (52 weeks) of treatment



Patients people with operable HER2-positive eBC
Size4805



Blindness double-blind Inclusion period
Follow-up duration Centers
Lost to FU geographical localisation
Primary endpoint iDFS Design Parallel groups



EndpointX1N1X0N0TE95% CI0,22,01,0

Links

Press Release

ClinicalTrial.gov record NCT01358877



Registering number NCT01358877 (see trial on clinicaltrials.gov)
Code Name BO25126, BIG 4-11

 

All trials of pertuzumab

Appears in following systematic reviews: